These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21802840)

  • 21. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
    Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
    Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
    Laussmann MA; Passante E; Hellwig CT; Tomiczek B; Flanagan L; Prehn JH; Huber HJ; Rehm M
    J Biol Chem; 2012 Apr; 287(18):14402-11. PubMed ID: 22408249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.
    Teng J; Hejazi S; Badr CE; Tannous BA
    Stem Cells; 2014 Aug; 32(8):2021-32. PubMed ID: 24801379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
    Sayers TJ; Brooks AD; Koh CY; Ma W; Seki N; Raziuddin A; Blazar BR; Zhang X; Elliott PJ; Murphy WJ
    Blood; 2003 Jul; 102(1):303-10. PubMed ID: 12637321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
    Park SA; Han HR; Ahn S; Ryu CH; Jeun SS
    Oncol Rep; 2021 Mar; 45(3):869-878. PubMed ID: 33469674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
    Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
    Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
    Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
    Koschny R; Holland H; Sykora J; Erdal H; Krupp W; Bauer M; Bockmuehl U; Ahnert P; Meixensberger J; Stremmel W; Walczak H; Ganten TM
    J Neurooncol; 2010 Apr; 97(2):171-85. PubMed ID: 19768634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
    Lu G; Punj V; Chaudhary PM
    Cancer Biol Ther; 2008 Apr; 7(4):603-8. PubMed ID: 18223318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas.
    Uzzaman M; Keller G; Germano IM
    Neuro Oncol; 2009 Apr; 11(2):102-8. PubMed ID: 18676359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells.
    Guo XR; Yang ZS; Tang XJ; Zou DD; Gui H; Wang XL; Ma SN; Yuan YH; Fang J; Wang B; Zhang L; Sun XY; Warnock GL; Dai LJ; Tu HJ
    Oncotarget; 2016 Aug; 7(34):55529-55542. PubMed ID: 27487125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
    Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S
    Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.